| Relating lipoprotein (a) concentrations to cardiovascular event risk after acute coronary syndrome: a comparison of 3 tests M Szarek, E Reijnders, JW Jukema, DL Bhatt, VA Bittner, R Diaz, S Fazio, ... Circulation 149 (3), 192-203, 2024 | 14 | 2024 |
| Quantitative protein mass-spectrometry requires a standardized pre-analytical phase NPM Smit, FP Romijn, VJJ van Ham, E Reijnders, CM Cobbaert, ... Clinical Chemistry and Laboratory Medicine (CCLM) 61 (1), 55-66, 2023 | 9 | 2023 |
| High residual cardiovascular risk after lipid-lowering: prime time for predictive, preventive, personalized, participatory, and psycho-cognitive medicine E Reijnders, A van der Laarse, JW Jukema, CM Cobbaert Frontiers in Cardiovascular Medicine 10, 1264319, 2023 | 6 | 2023 |
| Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling E Reijnders, A van der Laarse, LR Ruhaak, CM Cobbaert Clinical Proteomics 21 (1), 19, 2024 | 2 | 2024 |
| Comparison of change in lipoprotein (a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES M Szarek, E Reijnders, PG Steg, JW Jukema, M Schwertfeger, DL Bhatt, ... European Journal of Preventive Cardiology, zwae110, 2024 | 2 | 2024 |
| Quality Assurance for Multiplex Quantitative Clinical Chemistry Proteomics in Large Clinical Trials E Reijnders, FP Romijn, F Arslan, JJJ Georges, MM Pieterse, ... The Journal of Applied Laboratory Medicine, jfae092, 2024 | | 2024 |
| Unconfounded measurement of serum Lp (a) in upcoming Lp (a) lowering trials N Diederiks, N Smit, E Reijnders, F Romijn, M Pieterse, Y Van Der Burgt, ... Atherosclerosis 395, 2024 | | 2024 |
| RELATION OF LIPOPROTEIN (A) AND ITS REDUCTION BY ALIROCUMAB WITH INSULIN, INSULIN RESISTANCE, AND RISK OF NEW ONSET DIABETES AFTER ACUTE CORONARY SYNDROME GG Schwartz, M Szarek, JW Jukema, C Cobbaert, E Reijnders, V Bittner, ... Journal of the American College of Cardiology 83 (13_Supplement), 1964-1964, 2024 | | 2024 |
| Register now to R3i! Y Li, J Liu, N Huang Medicine 103, 6, 2024 | | 2024 |
| Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES M Szarek, PG Steg, JW Jukema, E Reijders, M Schwertfeger, D Bhatt, ... European Heart Journal 44 (Supplement_2), ehad655. 1447, 2023 | | 2023 |
